Skip to main content

Specialty Pharmacy

  • Sanofi to acquire Bioverativ for $11.6B

    The acquisition will see Sanofi adding the Waltham, Mass.-based biopharmaceutical company's hemophilia treatments Eloctate and Alprolix to its specialty and rare disease portfolio.
  • CVS Health adds rheumatoid arthritis to Transform Care offerings

    In a move aimed at helping its pharmacy benefits management clients control high specialty drug costs and improve patient outcomes, CVS Health has introduced the Transform Rheumatoid Arthritis Care program.
  • Industry Issues Summit: Charting a roadmap for patient-facing care

    There’s no single magic bullet for enabling patient-facing care in community-based pharmacy, but there are proven strategies to make substantial progress.

  • The Amazon question: How the online giant could shake up the Rx landscape

    Though CVS Health and Aetna have had a working relationship since 2010, and their pending merger had likely been in the works for some time, its timing, experts say, suggests that the merger is as much about staving off the looming threat from Amazon as it is about competing with top health insurers and retailers.

  • Diplomat CEO, chairman Hagerman retires

    Diplomat Pharmacy has announced that co-founder, CEO and chairman Phil Hagerman is retiring. The Flint, Mich.-based company has named board member Jeff Park as interim CEO, effective immediately. Hagerman will continue as a member of the board and become chairman emeritus, with Ben Wolin taking over as chairman, effective immediately.

  • PharmaJet, Invectys enter Phase 2 cancer vaccine trial

    Needle-free injection technology company PharmaJet, based in Golden, Colo., will be working with French biopharma company Invectys to test Invectys' therapeutic cancer vaccine. The Phase 2 trial is for INVAC-1, which uses PharmaJet’s needle-free injection system and is an immunotherapeutic DNA vaccine meant to treat cancer, the companies said.

  • Dr. Reddy’s reaches settlement regarding Consumer Product Safety Act compliance

    It has been announced by the United States subsidiary of Dr.Reddy’s Laboratories, that the company has reached a settlement with the U.S. Government in a case involving packaging for five blister-packed prescription products.

    In a joint filing, both parties have agreed to a settlement of the action without any adjudication or issue of fact or law. The matter has been settled for $5 million dollars, and the product in question has not been distributed in the packaging at issue since June 2012, the company said.

X
This ad will auto-close in 10 seconds